Unfortunately, this is not what these companies are doing, as a rule. And given what we've found out SSRIs -- and the behavior of some of the major players in this industry, in recent years -- no one should be terribly surprised at the findings in the JAMA study (assuming they hold up to scrutiny).
Also:
Restarting the SSRI of course did the trick, but they don't work fast and I lost nearly a year of my life. I currently regard this as the worst decision I have ever made.
With all due respect to your situation -- and not intended in the least to belittle either your suffering, or the thought you put into the decisions you made -- perhaps the bigger mistake was not going off SSRIs (at which point the die may have been more or less cast for you, in the short- to medium-term) -- but agreeing to go on them in the first place.
[1] Yes, this is a loaded term. But I use it quite intentionally. Having not only studied the tradeoffs associated with one major class of antidepressants, but also having worked for one of the market's leading distributors -- and having made a careful study of their marketing materials -- I'd say "pushing" is not a bad description for the aggressive marketing tactics these companies have used over the years.